Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Share...
November 20 2020 - 11:00AM
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the
“Company”), today announced that it has filed an investor
presentation with the U.S. Securities and Exchange Commission
detailing the Company’s track record of successful developments and
accomplishments within the oncology space as well as its commitment
to evolving its Board of Directors (the “Board”) to drive
shareholder value.
Highlights from the Ziopharm investor
presentation include:
- Ziopharm’s significant progress on
its strategy to develop and commercialize non-viral and
cytokine-driven cell and gene therapies to treat the millions of
people globally diagnosed with a solid tumor each year since its
separation from Precigen in 2018;
- Significant anticipated pipeline
development milestones expected to enhance shareholder value;
and
- The Board’s governance changes and
continued commitment to refreshing and enhancing its membership,
with more than half of the current directors being appointed to the
Board since June 2019, a process undertaken following shareholder
feedback.
Commenting on the investor presentation,
Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm,
stated, “Over the course of the past several weeks, we have
continued to address shareholder feedback with additional Board
changes in the appointment of Mary Thistle and resignation of Dr.
Scott Braunstein. We also reported key new executive hires and
strong third quarter results that demonstrate our continued
execution and clinical progress to advance our mission to treat
cancer patients with potentially transformational therapies. Our
recent investor presentation outlines these positive changes and
strategic initiatives as well as an array of other facts and
upcoming catalysts that we believe help advance our goal of
delivering long-term shareholder value.”
Industry analysts who closely follow Ziopharm
have noted this progress and outlook, illustrated by the below
selected commentary:
- “By unlocking the potential of its Sleeping Beauty technology,
the Company is poised to deliver a leap forward in the
personalization of cancer therapy.”1
- “ZIOP is a refreshed, and unencumbered oncology story, with two
exciting technology platforms.”2
- “We believe ZIOP is doing
everything it proactively can, to hit the ground running with the
TCR T trials, with two INDs …this opportunistic move will likely
yield long term benefits for the program.”3
Ziopharm recommends shareholders sign and return
the Company’s GREEN Consent Revocation Card. The
investor presentation and other important materials related to the
WaterMill consent solicitation can be found at
www.ZiopharmForward.com.
About Ziopharm Oncology,
Inc.Ziopharm is developing non-viral and cytokine-driven
cell and gene therapies that weaponize the body’s immune system to
treat the millions of people globally diagnosed with a solid tumor
each year. With its multiplatform approach, Ziopharm is at the
forefront of immuno-oncology with a goal to treat any type of solid
tumor. Ziopharm’s pipeline is built for commercially scalable, cost
effective T-cell receptor T-cell therapies based on its non-viral
Sleeping Beauty gene transfer platform, a precisely controlled
IL-12 gene therapy, and rapidly manufactured Sleeping
Beauty-enabled CD19-specific CAR-T program. The Company has
clinical and strategic partnerships with the National Cancer
Institute, The University of Texas MD Anderson Cancer Center and
others. For more information, please visit www.ziopharm.com.
Forward-Looking Statements This
press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts, and in some cases can be identified by terms such as "may,"
"will," "could," "expects," "plans," "anticipates," and "believes."
These statements include, but are not limited to, statements
regarding the growth of Ziopharm from a development-stage entity to
a commercial-stage company, development of its clinical portfolio
and research and development programs. Although Ziopharm’s
management team believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Ziopharm, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, changes in our operating plans that may impact
our cash expenditures, the uncertainties inherent in research and
development, future clinical data and analysis, including whether
any of Ziopharm’s product candidates will advance further in the
preclinical research or clinical trial process, including receiving
clearance from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies to conduct clinical trials
and whether and when, if at all, they will receive final approval
from the U.S. FDA or equivalent foreign regulatory
agencies and for which indication; the strength and enforceability
of Ziopharm’s intellectual property rights; competition from other
pharmaceutical and biotechnology companies as well as risk factors
discussed or identified in the public filings with
the Securities and Exchange Commission made by Ziopharm,
including those risks and uncertainties listed in Ziopharm’s
Quarterly Report on Form 10-Q filed by Ziopharm with
the Securities and Exchange Commission. We are providing this
information as of the date of this press release, and Ziopharm does
not undertake any obligation to update or revise the information
contained in this press release whether as a result of new
information, future events or any other reason.
Important Additional Information and
Where to Find ItZiopharm has filed a definitive consent
revocation statement (the “Consent Revocation Statement”) together
with a GREEN consent revocation card with the SEC
in connection with the Consent Solicitation. SHAREHOLDERS ARE URGED
TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS
OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT
ZIOPHARM FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY
BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
Shareholders will be able to obtain, free of charge, copies of the
Consent Revocation Statement (including the GREEN
consent revocation card), any amendments or supplements thereto and
any other documents that Ziopharm files with the SEC from the SEC’s
website (http://www.sec.gov) or from Ziopharm’s website
(www.ziopharm.com) by clicking on “Investors” and then “SEC
Filings.”
Investor Relations
Contacts:Adam D. Levy, PhD, MBAEVP, Investor Relations and
Corporate Communications(508) 552-9255alevy@ziopharm.com
Chris Taylor VP, Investor Relations and
Corporate Communications(617) 502-1881ctaylor@ziopharm.com
Michael VerrechiaMorrow Sodali(212)
300-2476m.verrechia@morrowsodali.com
Media Relations Contacts:Chris
Kittredge, Andrew Cole and Zachary TramontiSard Verbinnen &
Co.Ziopharm-SVC@sardverb.com
1 Lake Street Capital, “Wait Continues for Patient Enrollments
In T-Cell Programs,” (November 6, 2020)Permission to quote third
parties neither requested nor granted. 2 Jefferies Group, “3Q20:
Library TCRT IND on Track in 1Q21; IL12 Updates at SNO,” (November
6, 2020)Permission to quote third parties neither requested nor
granted.3 Cantor Fitzgerald, “2Q Update: Solid clinical execution
on pipeline, in light of pandemic headwinds,” (August 12, 2020)
Permission to quote third parties neither requested nor
granted.
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2023 to Apr 2024